Alnylam Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
ALNY
CUSIP
02043Q107
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 02043Q107 since 12/18/2024, largest first.

Filer % of Class Filed
Capital World Investors 13G/A 10.4% 11/13/2026
Event 9/30/2026
FMR LLC 13G/A
9.5% 11/5/2026
Event 9/30/2026
Capital Research Global Investors 13G/A 8.2% 11/13/2026
Event 9/30/2026
T. Rowe Price Investment Management, Inc. 13G 7.5% 11/16/2026
Event 9/30/2026
Vanguard Capital Management LLC 13G 5.4% 4/29/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.0% 10/30/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 737 136 M $33.4B
2026 Q2 803 133 M $42.3B
2026 Q1 805 131 M $43.4B
2025 Q4 862 134 M $53.2B
2025 Q3 834 136 M $60.2B
2025 Q2 666 134 M $43.1B
2025 Q1 645 131 M $34.8B
2024 Q4 607 129 M $30.1B
2024 Q3 580 125 M $34.0B
2024 Q2 537 120 M $29.2B
2024 Q1 511 115 M $17.2B
2023 Q4 506 117 M $22.4B
2023 Q3 464 118 M $20.8B
2023 Q2 481 119 M $22.5B
2023 Q1 482 120 M $24.0B
2022 Q4 498 120 M $28.4B
2022 Q3 503 133 M $26.7B
2022 Q2 439 114 M $16.6B
2022 Q1 453 114 M $18.6B
2021 Q4 441 112 M $19.0B
2021 Q3 410 112 M $21.1B
2021 Q2 409 112 M $19.0B
2021 Q1 397 109 M $15.4B
2020 Q4 380 108 M $14.1B
2020 Q3 365 108 M $15.8B
2020 Q2 382 112 M $16.5B
2020 Q1 339 108 M $11.8B
2019 Q4 321 106 M $12.3B
2019 Q3 285 108 M $8.69B
2019 Q2 293 106 M $7.70B
2019 Q1 297 96.9 M $9.06B
2018 Q4 286 92.5 M $6.74B
2018 Q3 311 90.9 M $7.96B
2018 Q2 315 92.0 M $9.06B
2018 Q1 302 91.6 M $10.9B
2017 Q4 286 92.2 M $11.7B
2017 Q3 246 87.6 M $10.3B
2017 Q2 232 87.2 M $6.95B
2017 Q1 208 82.3 M $4.22B
2016 Q4 213 79.9 M $2.99B
2016 Q3 265 77.6 M $5.25B
2016 Q2 256 74.1 M $4.13B
2016 Q1 257 72.1 M $4.45B
2015 Q4 261 66.0 M $6.24B
2015 Q3 258 65.4 M $5.26B
2015 Q2 279 65.6 M $7.86B
2015 Q1 238 64.5 M $6.73B
2014 Q4 216 58.0 M $5.65B
2014 Q3 186 59.0 M $4.61B
2014 Q2 195 57.8 M $3.65B
2014 Q1 201 55.7 M $3.74B